Retrospective, monocentric clinical study to evaluate the impact of induction therapy in patients with IIIA N2 lung cancer following surgical resection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013150

Enrollment

100

Registered

2017-10-23

Start date

2017-04-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Patients with histologic proven Stage IIIA N2 NSCLC. In case of proven mediastinal lymph node involvement application of two cycles platinum-based chemotherapy as induction followed by surgic

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Stage IIIA N2 NSCLC written informed consent resectable tumor Induction therapy resection between 01.01.2009 and 31.12.2016

Exclusion criteria

Exclusion criteria: no written informed consent irresectable tumor

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
diesease free survival	—

Countries

Germany

Contacts

Public ContactBenedikt Haager

Universitätsklinikum Freiburg

benedikt.hsager@uniklinik-freiburg.de+49-761-27024010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026